|
1) Dick JE, Lapidot T. Biology of normal and acute myeloid leukemia stem cells. Int J Hematol. 2005; 82: 389-96
|
|
|
|
2) Kimura T, Matsuoka Y, Murakami M, et al. In vivo dynamics of human cord blood-derived CD34(-)SCID-repopulating cells using intra-bone marrow injection. Leukemia. 2010; 24: 162-8
|
|
|
|
|
|
3) Ito M, Hiramatsu H, Kobayashi K, et al. NOD/SCID/gamma (c) (null) mouse: an excellent recipient mouse model for engraftment of human cells. Blood. 2002; 100: 3175-82
|
|
|
|
|
|
4) Traggiai E, Chicha L, Mazzucchelli L, et al. Development of a human adaptive immune system in cord blood cell-transplanted mice. Science (New York). 2004; 304: 104-7
|
|
|
|
|
|
5) Ishikawa F, Yasukawa M, Lyons B, et al. Development of functional human blood and immune systems in NOD/SCID/IL2 receptor {gamma} chain (null) mice. Blood. 2005; 106: 1565-73
|
|
|
|
|
|
6) Taussig DC, Miraki-Moud F, Anjos-Afonso F, et al. Anti-CD38 antibody-mediated clearance of human repopulating cells masks the heterogeneity of leukemia-initiating cells. Blood. 2008; 112: 568-75
|
|
|
|
|
|
7) le Viseur C, Hotfilder M, Bomken S, et al. In childhood acute lymphoblastic leukemia, blasts at different stages of immunophenotypic maturation have stem cell properties. Cancer Cell. 2008; 14: 47-58
|
|
|
|
|
|
8) Tanizaki R, Nomura Y, Miyata Y, et al. Irrespective of CD34 expression, lineage-committed cell fraction reconstitutes and re-establishes transformed Philadelphia chromosome-positive leukemia in NOD/SCID/IL-2Rgammac-/- mice. Cancer Sci. 2010; 101: 631-8
|
|
|
|
|
|
9) Ishikawa F, Yoshida S, Saito Y, et al. Chemotherapy-resistant human AML stem cells home to and engraft within the bonemarrow endosteal region. Nat Biotechnol. 2007; 25: 1315-21
|
|
|
|
|
|
10) Saito Y, Uchida N, Tanaka S, et al. Induction of cell cycle entry eliminates human leukemia stem cells in a mouse model of AML. Nat Biotechnol. 28: 275-80
|
|
|
|
|
|
11) Arai F, Yoshihara H, Hosokawa K, et al. Niche regulation of hematopoietic stem cells in the endosteum. Ann NY Acad Sci. 2009; 1176: 36-46
|
|
|
|
|
|
12) Essers MA, Offner S, Blanco-Bose WE, et al. IFN alpha activates dormant haematopoietic stem cells in vivo. Nature. 2009; 458: 904-8
|
|
|
|
|
|
13) Sato T, Onai N, Yoshihara H, et al. Interferon regulatory factor-2 protects quiescent hematopoietic stem cells from type I interferon-dependent exhaustion. Nat Med. 2009; 15: 696-700
|
|
|
|
|
|
14) Essers MA, Trumpp A. Targeting leukemic stem cells by breaking their dormancy. Mol Oncol. 2010; 4: 443-50
|
|
|
|
|
|
15) Zeng Z, Shi YX, Samudio IJ, et al. Targeting the leukemia microenvironment by CXCR4 inhibition overcomes resistance to kinase inhibitors and chemotherapy in AML. Blood. 2009; 113: 6215-24
|
|
|
|
|
|
16) Jordan CT. Targeting myeloid leukemia stem cells. Sci Transl Med. 2010; 2: 31ps21
|
|
|
|
|
|
17) Majeti R, Chao MP, Alizadeh AA, et al. CD47 is an adverse prognostic factor and therapeutic antibody target on human acute myeloid leukemia stem cells. Cell. 2009; 138: 286-99
|
|
|
|
|
|
18) Saito Y, Kitamura H, Hijikata A, et al. Identification of therapeutic targets for quiescent, chemotherapy-resistant human leukemia stem cells. Sci Transl Med. 2010; 2: 17ra19
|
|
|
|
|